PTLD, or post-transplant lymphoproliferative disorder, is a type of cancer that develops in people who have received an organ or stem cell transplant. It occurs when immune-suppressing medications, taken to prevent organ rejection, allow certain white blood cells to grow uncontrollably. PTLD accounts for a small but significant percentage of cancers in transplant recipients, with rates ranging from about 0.6% in kidney transplant patients to 1.5% in lung transplant recipients.
How PTLD Develops
To prevent your body from rejecting a transplanted organ, you take medications that deliberately weaken your immune system. This creates a vulnerability. In a healthy person, immune cells called cytotoxic T-cells act as a surveillance system, identifying and destroying cells that start behaving abnormally. When those T-cells are suppressed by anti-rejection drugs, abnormal cells can multiply unchecked.
In most cases, the Epstein-Barr virus (EBV) is the driving force. EBV is extremely common: most adults carry it without symptoms. The virus infects a type of white blood cell called B-cells and produces proteins that mimic normal growth signals, essentially tricking B-cells into multiplying. One viral protein acts like a permanent “on” switch for cell growth, while another sends survival signals that keep infected cells from dying off naturally. In someone with a fully functioning immune system, T-cells quickly shut this process down. In a transplant patient on immunosuppression, the virus can push B-cell growth from harmless to precancerous to full lymphoma.
Who Is Most at Risk
The single biggest risk factor is being EBV-negative before transplant. If you’ve never been exposed to the virus and then encounter it while immunosuppressed, your body has no existing defenses. Studies of U.S. kidney transplant recipients found that EBV-negative patients had roughly three times the risk of developing early PTLD compared to those who were EBV-positive before surgery.
Young age at transplant is closely tied to this. Children and teenagers are more likely to be EBV-naive, which largely explains why recipients under 20 face nearly four times the risk of early PTLD compared to those transplanted between ages 20 and 50. The type of organ matters too. Multiorgan and intestinal transplant recipients carry the highest relative risk, followed by lung, pancreas, liver, heart, and kidney recipients, in that order. More intensive immunosuppression generally means higher risk.
The Four Types of PTLD
The World Health Organization classifies PTLD into four categories based on how the abnormal cells look under a microscope:
- Early lesions: The mildest form, where B-cells are proliferating but haven’t yet formed a true cancer. These sometimes resolve when immunosuppression is reduced.
- Polymorphic PTLD: A mix of different cell types that is more disorganized than a typical lymphoma but still potentially dangerous.
- Monomorphic PTLD: The most common category, resembling a standard lymphoma. Diffuse large B-cell lymphoma is the most frequent subtype, making up 50 to 75% of monomorphic cases.
- Classic Hodgkin lymphoma type: A less common form that closely resembles Hodgkin lymphoma seen in non-transplant patients.
A tissue biopsy is the only way to determine which type you have, and the distinction matters because treatment differs for each.
Common Symptoms
PTLD can show up in many parts of the body, which makes it tricky to recognize. The most common signs include swollen lymph nodes, unexplained fevers, night sweats, weight loss, and fatigue. Some patients develop masses in the transplanted organ itself or in the gastrointestinal tract, leading to abdominal pain or changes in bowel habits. Because these symptoms overlap with infections and other post-transplant complications, PTLD requires a high index of suspicion. Any transplant recipient with persistent, unexplained symptoms like these should be evaluated promptly.
How PTLD Is Diagnosed
Diagnosis requires a tissue biopsy, ideally a full excisional biopsy rather than a needle sample, so pathologists can examine the cell architecture in detail. The tissue is tested for specific markers on the cell surface and stained for EBV-encoded RNA (called EBER staining), which confirms whether the virus is driving the disease. This distinction between EBV-positive and EBV-negative PTLD influences treatment decisions. Experienced blood cancer pathologists are important here because PTLD subtypes can be difficult to classify correctly.
After transplant, many centers monitor EBV levels in the blood as an early warning system. For stem cell transplant patients, European guidelines recommend weekly monitoring starting within the first month and continuing for at least four months. A rapidly rising viral load, which can double in as little as 56 hours, may prompt preventive treatment before PTLD develops. There is no universally agreed-upon threshold for when to intervene, with different centers using different cutoffs.
Treatment Approach
The first step in treating PTLD is reducing immunosuppression. This allows your own immune system to partially recover and begin fighting the abnormal cells. In practice, this typically means cutting the dose of certain anti-rejection drugs by at least half and stopping others, while continuing steroids. For early lesions, this alone can sometimes be enough.
For most patients with polymorphic or monomorphic PTLD, the standard of care adds rituximab, a targeted therapy that destroys B-cells by binding to a protein called CD20 on their surface. The current recommended approach, called risk-stratified sequential treatment, starts with immunosuppression reduction, adds rituximab, and then escalates to chemotherapy only for patients whose disease doesn’t respond. This stepwise strategy avoids exposing everyone to the toxicity of chemotherapy when some patients will respond to less aggressive treatment.
For patients whose PTLD comes back or doesn’t respond to initial treatment, the outlook has historically been poor. Stem cell transplant recipients with relapsed disease who received standard second-line therapies had a median survival of less than one month. A newer option called tabelecleucel uses donor T-cells specifically trained to recognize and kill EBV-infected cells. In clinical trials, about half of patients responded, with a median response lasting 23 months. One-year survival rates reached approximately 61% overall, a substantial improvement over usual care for this difficult situation.
Survival and Prognosis
Outcomes for PTLD have improved significantly over the past two decades. In children with kidney transplants, survival after a PTLD diagnosis is roughly 91% at one year and 87% at five years. Adult survival varies more widely depending on the PTLD subtype, how early it’s caught, and whether it responds to initial treatment. EBV-positive cases, particularly early lesions and polymorphic forms, tend to respond better to immunosuppression reduction and rituximab. EBV-negative PTLD often behaves more like an aggressive lymphoma in the general population and may require chemotherapy sooner.
Graft survival is a separate concern. Among pediatric kidney transplant recipients who developed PTLD, the transplanted kidney was still functioning in about 82% at one year, dropping to 65% at five years. The reduction in immunosuppression needed to treat PTLD increases the risk of organ rejection, creating a difficult balancing act between fighting the cancer and preserving the transplant.